达格列净减少DAPA-HF试验中丧失的全健康天数
DAPA-HF试验纳入NYHA II-IV级且LVEF≤40%的心衰患者,比较达格列净与安慰剂对包含死亡、住院及健康受损所致全健康损失天数的综合指标的影响。结果显示达格列净组360天内因心血管死亡和心衰住院损失天数少于安慰剂组,且获益随时间增加。
要点
- 达格列净减少因心血管死亡和心衰住院损失的天数。
- 达格列净减少全因死亡和住院损失的天数。
- 综合健康损失天数的获益在1年内随时间增加。
核心结论
- 达格列净减少了因死亡、住院和健康受损所致的潜在全健康损失总天数,且该获益在1年内随时间增加。
研究设计与样本
- DAPA-HF试验的事后分析,纳入NYHA II-IV级、LVEF≤40%的心衰患者,比较达格列净与安慰剂。
- 达格列净组n=2,127,安慰剂组n=2,108。
主要发现
- 360天内,达格列净组因心血管死亡和心衰住院损失10.6±1.0天(2.9%),安慰剂组损失14.4±1.0天(4.0%),差值为-3.8天(95%CI:-6.6至-1.0天)。
- 达格列净组全因死亡和住院损失天数少于安慰剂组(15.5±1.1天[4.3%] vs 20.3±1.1天[5.6%])。
- 加入根据KCCQ总体评分调整的健康受损额外损失天数后,达格列净组总损失110.6±1.6天(30.7%),安慰剂组116.9±1.6天(32.5%)。
- 两组间所有指标的差异随时间增加:死亡和住院损失天数差值在120天为-0.9天(-0.7%),240天为-2.3天(-1.0%),360天为-4.8天(-1.3%)。
临床怎么用
- 对于NYHA II-IV级且LVEF≤40%的心衰患者,达格列净可减少因死亡、住院和健康受损损失的全健康天数,支持其用于改善整体健康状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conventional time-to-first-event analyses cannot incorporate recurrent hospitalizations and patient well-being in a single outcome. OBJECTIVES: To overcome this limitation, we tested an integrated measure that includes days lost from death and hospitalization, and additional days of full health lost through diminished well-being. METHODS: The effect of dapagliflozin on this integrated measure was assessed in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial, which examined the efficacy of dapagliflozin, compared with placebo, in patients with NYHA functional class II to IV heart failure and a left ventricular ejection fraction ≤40%. RESULTS: Over 360 days, patients in the dapagliflozin group (n = 2,127) lost 10.6 ± 1.0 (2.9%) of potential follow-up days through cardiovascular death and heart failure hospitalization, compared with 14.4 ± 1.0 days (4.0%) in the placebo group (n = 2,108), and this component of all measures of days lost accounted for the greatest between-treatment difference (-3.8 days [95% CI: -6.6 to -1.0 days]). Patients receiving dapagliflozin also had fewer days lost to death and hospitalization from all causes vs placebo (15.5 ± 1.1 days [4.3%] vs 20.3 ± 1.1 days [5.6%]). When additional days of full health lost (ie, adjusted for Kansas City Cardiomyopathy Questionnaire-overall summary score) were added, total days lost were 110.6 ± 1.6 days (30.7%) with dapagliflozin vs 116.9 ± 1.6 days (32.5%) with placebo. The difference in all measures between the 2 groups increased over time (ie, days lost by death and hospitalization -0.9 days [-0.7%] at 120 days, -2.3 days [-1.0%] at 240 days, and -4.8 days [-1.3%] at 360 days). CONCLUSIONS: Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure; NCT03036124).
引用
- Kondo T, Mogensen UM, Talebi A, et al. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. J Am Coll Cardiol. 2024. PMID: 38537918. doi:10.1016/j.jacc.2024.03.385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。